CC214-2
CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473) . CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219) -resistant signaling and the growth of glioblastomas in vitro and in vivo[1][2].
Product Specifications
CAS Number
[1228012-18-7]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; mTOR
Type
Reference compound
Related Pathways
Autophagy; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cc214-2.html
Purity
98.41
Solubility
DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 70°C)
Smiles
O=C1N=C2NC=C(C3=CC=C(C(C)(C)O)N=C3)N=C2N(CC4CCOCC4)C1
Molecular Formula
C20H25N5O3
Molecular Weight
383.44
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MTORC1; mTORC2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
PLAC5 CRISPRa sgRNA lentivector (set of three targets)(Human)
